AptarGroup (ATR) Stock Rallies As Q3 Results Highlight Margin Strain

Simply Wall St.10-31 09:43

AptarGroup walked into this Q3 2026 print with a premium P/E of 32.6x and a reputation as a steady compounder in packaging and drug delivery. The share price then jumped 5.0% on the first trading day ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2679422143?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2041000-choice1-card/1788999950776","is_english":true,"pubTime":"2026-10-31 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2679422143","market":"hk","top_or_hot":-1,"title":"AptarGroup (ATR) Stock Rallies As Q3 Results Highlight Margin Strain","media":"Simply Wall St.","content":"<div>\n<p>AptarGroup walked into this Q3 2026 print with a premium P/E of 32.6x and a reputation as a steady compounder in packaging and drug delivery. The share price then jumped 5.0% on the first trading day ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/aptargroup-atr-stock-rallies-as-q3-results-highlight-margin\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AptarGroup (ATR) Stock Rallies As Q3 Results Highlight Margin Strain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptarGroup (ATR) Stock Rallies As Q3 Results Highlight Margin Strain\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-31 09:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/aptargroup-atr-stock-rallies-as-q3-results-highlight-margin><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AptarGroup walked into this Q3 2026 print with a premium P/E of 32.6x and a reputation as a steady compounder in packaging and drug delivery. The share price then jumped 5.0% on the first trading day ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/aptargroup-atr-stock-rallies-as-q3-results-highlight-margin\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7095","symbol_name":"多种金属与采矿","start_time":0,"source_url":"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/aptargroup-atr-stock-rallies-as-q3-results-highlight-margin","article_id":"2679422143","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/2041000-choice1-card/1788999950776"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/aptargroup-atr-stock-rallies-as-q3-results-highlight-margin","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2679422143","pubTimestamp":1793411006,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"AptarGroup walked into this Q3 2026 print with a premium P/E of 32.6x and a reputation as a steady compounder in packaging and drug delivery. The share price then jumped 5.0% on the first trading day after results, even as adjusted earnings per share for the quarter landed at the lower end of its recent range and net profit margin on a trailing basis sat at 6.7%, well below last year. That clash between a richer valuation and tighter profitability is the real story investors now need to...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7095":"多种金属与采矿","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","ATR.AU":"ASTRON CORP LTD-CDI","ATR":"Aptar","BK4126":"金属与玻璃容器","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC"},"translate_title":"第三季度业绩凸显利润率紧张，AptarGroup (ATR) 股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATR.AU":1.5,"ATR":1.5},"content_text":"AptarGroup walked into this Q3 2026 print with a premium P/E of 32.6x and a reputation as a steady compounder in packaging and drug delivery. The share price then jumped 5.0% on the first trading day after results, even as adjusted earnings per share for the quarter landed at the lower end of its recent range and net profit margin on a trailing basis sat at 6.7%, well below last year. That clash between a richer valuation and tighter profitability is the real story investors now need to weigh. Appreciate AptarGroup's reputation as a steady compounder, but a 32.6x P/E appears high relative to its 6.7% trailing net margin. Compare that profile with our list of solid balance sheet and fundamentals stocks (25 results). AdvertisementQ3 2026 Earnings Summary  Revenue (Q3 2026 vs. Q3 2025): US$1,019.1m compared with US$961.1m (up about 6.0%) Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$32.6m compared with US$127.9m (down about 74.5%) Basic EPS (Q3 2026 vs. Q3 2025): US$0.51 compared with US$1.95 (down about 73.6%) Adjusted EBITDA Margin (Q3 2026 vs. Q3 2025): 21.3% compared with about 23.2% (down about 190 basis points)  Earnings only tell part of AptarGroup's story, since cash flows often give you a clearer picture of what you are actually paying for in NYSE:ATR. Looking at AptarGroup's cash generation alone, the stock could be a striking 33% undervalued. NYSE:ATR Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026 AptarGroup’s Pharma Ambition Meets Early Proof Points AptarGroup’s bullish pitch hinges on pharma devices and services becoming a true earnings engine rather than just a storyline. \"Bullish analysts expect AptarGroup to turn its expanding nasal and systemic nose to brain drug delivery work into a higher margin pharma growth engine that deepens customer reliance on its devices and services.\"Q3 shows real, if early, traction. Pharma core sales were flat on the surface, yet excluding emergency medicine destocking they rose 8%, with adjusted EBITDA margin at 36.4%. Intranasal devices now carry EU MDR CE marking; clinical nasal programs are running through Phase II and III; and the Pulmotree and Stevanato deals give customers clearer paths from trials to launch. The price and this Narrative do not agree. → Uncover what this Narrative says AptarGroup is actually worth. AptarGroup Bear Case: Margin Strain Still Visible The harsher view centers on AptarGroup struggling to turn regulatory and sustainability pressure into a profitable packaging and pharma mix. \"Margin pressures stem from shifts in packaging trends, normalization of key pharma products, and rising legal and sustainability-related costs dampening earnings and cash flow.\"Q3 results give this concern real footing. Adjusted EBITDA margin slipped 190 bps to 21.3%, with Beauty and Closures both showing thinner profitability despite solid core sales. Pharma margin eased 80 bps as emergency medicine destocking hit a richer line. Management also flagged multiquarter legal costs and higher sustainability capex, so the margin repair job is clearly incomplete this quarter. Hunt For Mispriced Earnings Power AptarGroup illustrates how a richer multiple can coexist with pressured profitability. The real opportunity is in stocks that could be undervalued before the market adjusts their earnings power.  Company 1 - 38% below our estimate - turns a record high-horsepower engine backlog and data center power contracts into expanded capacity and focused capital spending. Company 2 - 37% below our estimate - tightens AI driven freight-matching and carrier vetting so heavy haul loads run with fewer disputes, delays and claims. Company 3 - 48% below our estimate - converts a record backlog of data center and modular projects into higher margin work with remote monitoring and disciplined execution.  That is three of the list. See every one of the 29 undervalued companies on it → This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2679422143","isCrawlerRequest":true}